CD Biosynsis provides professional Biotin-Antibody Conjugation services, offering a robust and versatile platform for the development of high-sensitivity detection tools. Biotinylation of antibodies exploits the extraordinary affinity between biotin and streptavidin, which is one of the strongest non-covalent biological interactions known. This platform allows for the efficient labeling of IgG, IgM, and antibody fragments (Fab, scFv), enabling their use in a wide array of applications including ELISA, Western blotting, immunohistochemistry (IHC), and flow cytometry.
Our technical team focuses on maintaining the immunoreactivity and structural integrity of the antibody during the conjugation process. By carefully optimizing the biotin-to-antibody ratio and selecting appropriate spacer arms, we prevent the "masking" of the antigen-binding sites (CDRs). Whether you require random surface labeling or site-specific enzymatic conjugation, our services deliver high-purity conjugates with verified binding affinity and optimized signal-to-noise ratios.
Get a QuoteThe primary advantage of biotin-antibody conjugation is signal amplification. Because multiple biotin molecules can be attached to a single antibody, and each streptavidin molecule can bind up to four biotins, a secondary detection layer (linked to HRP, AP, or fluorophores) can significantly lower the limit of detection for your target antigen. This is essential for identifying low-abundance proteins in complex clinical or environmental samples.
We utilize advanced "Long Chain" (LC) and PEGylated linkers to ensure that the biotin tag is physically accessible to streptavidin probes. Short linkers can often lead to the biotin being buried within the protein folds of the antibody, leading to poor capture efficiency. Our platform evaluates the antibody isotype and species to select the chemical reactive group—such as NHS-esters for amines or maleimides for hinge-region thiols—that provides the most stable and functional conjugate for your specific assay requirements.
The most common method targeting lysine residues. Ideal for general-purpose detection antibodies.
Targeting hinge-region cysteines. Provides better orientation and prevents interference with the antigen-binding site.
Targeting Asp/Glu residues, useful for acidic antibodies or when amines are critical for function.
Absolute site-specificity via AviTag, ensuring a 1:1 ratio and perfect antibody orientation on surfaces.
Utilizing specialized biocatalysts to attach biotin to defined peptide motifs or glycan chains.
DOL Optimization
Precise control of the Degree of Labeling to maximize signal while preventing antibody precipitation.
Our systematic workflow ensures high labeling efficiency and thorough removal of unreacted reagents.
1. Pre-Conjugation Prep
2. Conjugation Reaction
3. High-Res Purification
4. Quality Control
Buffer exchange into amine-free buffers (e.g., PBS). Removal of stabilizing proteins like BSA or sodium azide which interfere with the reaction.
Incubation with optimized molar excesses of biotin-NHS or biotin-maleimide. Careful temperature and pH control to preserve antibody tertiary structure.
Quantification of the Degree of Labeling (DOL) via HABA assay. Verification of antigen binding via ELISA. Purity check via SDS-PAGE.
High Signal-to-Noise
Optimization of labeling density to ensure maximum detection sensitivity with minimal non-specific background binding.
Activity Retention
Selection of spacer arms and reactive groups that protect the CDR regions, ensuring full antigen-binding affinity.
Isotype Expertise
Specialized protocols for fragile antibody formats including IgM, Fab fragments, and scFv recombinant antibodies.
Bespoke Linkers
Access to a library of PEGylated and cleavable linkers to suit specialized applications like pull-down or cell-surface labeling.
1. How many biotin molecules are typically attached per antibody?
For a standard IgG, we typically target a Degree of Labeling (DOL) of 3 to 6 biotin molecules. This provides a high signal without causing the antibody to aggregate or lose binding affinity.
2. Can I biotinylate an antibody that is currently in a buffer with BSA?
No. BSA contains many primary amines that will compete for the biotin reagent. We must perform a purification step (e.g., Protein A/G) or use specialized kits to remove BSA before conjugation.
3. What is the advantage of using a PEGylated biotin linker?
PEG linkers are hydrophilic, which improves the solubility of the antibody conjugate and provides a flexible spacer that reduces steric hindrance during streptavidin binding.
4. How do you ensure the biotinylation doesn't block the antigen binding site?
We utilize site-selective strategies, such as sulfhydryl-reactive labeling in the hinge region or enzymatic C-terminal labeling, to keep the CDR regions free and accessible.
5. How long is a biotinylated antibody stable?
When stored correctly at 4°C in a stabilizing buffer with a preservative (like sodium azide), biotinylated antibodies are typically stable for 6 to 12 months.
6. Do you provide validation data for the conjugate?
Yes. Every batch includes a COA (Certificate of Analysis) with the determined DOL and a purity check via HPLC or SDS-PAGE.
7. Is it possible to use biotinylation for antibody fragments like Fab?
Absolutely. Because fragments are smaller, we often recommend site-specific methods to ensure the biotin tag doesn't interfere with binding in the limited surface area available.
8. What is the typical turnaround time?
A standard biotin-antibody conjugation project, including purification and quality control, typically takes 2 to 3 weeks.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.